Brind.

Alexander is appointed CEO of Ovid Therapeutics, which develops medicines in the US and could benefit from Trump-era tariffs. Charles Carter was promoted to CFO.

1 report, 1 independent Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Alexander is appointed CEO of Ovid Therapeutics, which develops medicines in the US and could benefit from Trump-era tariffs. Charles Carter was promoted to CFO.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped